Influence of tumor cavitation on assessing the clinical benefit of anti-PD1 or PD-L1 inhibitors in advanced lung squamous cell carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Influence of tumor cavitation on assessing the clinical benefit of anti-PD1 or PD-L1 inhibitors in advanced lung squamous cell carcinoma
Authors
Keywords
-
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-03
DOI
10.1016/j.cllc.2023.10.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
- (2023) Silvia Novello et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights
- (2022) Antonella Cammarota et al. Journal of Hepatocellular Carcinoma
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- (2021) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- A Single-Center 10-Year Retrospective Analysis of Cryoablation for the Management of Desmoid Tumors
- (2021) Yet Y. Yan et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- KRAS Mutations in Squamous Cell Carcinomas of the Lung
- (2021) Fabian Acker et al. Frontiers in Oncology
- mRECIST for HCC: Performance and novel refinements
- (2020) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
- (2020) Flora Mulkey et al. Journal for ImmunoTherapy of Cancer
- Cavitation and fatal hemoptysis after immunotherapy for advanced lung adenocarcinoma: A case report
- (2020) Ruijuan Wang et al. Thoracic Cancer
- Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
- (2020) Claudia Parisi et al. Journal for ImmunoTherapy of Cancer
- Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
- (2020) Narjess Ayati et al. JOURNAL OF NUCLEAR MEDICINE
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
- (2020) Mary W Redman et al. LANCET ONCOLOGY
- Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria
- (2019) Martina Vivoda Tomšič et al. CANCER IMAGING
- Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
- (2019) Francesco Facchinetti et al. Immunotherapy
- Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment
- (2019) Kentaro Masuhiro et al. Journal of Thoracic Oncology
- Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
- (2019) Mª Pilar Solis-Hernandez et al. BRITISH JOURNAL OF CANCER
- Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?
- (2019) Lorenzo Calvetti et al. Translational Lung Cancer Research
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC
- (2018) Angel Artal-Cortés et al. Journal of Thoracic Oncology
- mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study
- (2018) S. Mazzeo et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation
- (2016) Marco Dioguardi Burgio et al. LIVER TRANSPLANTATION
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Significance of different response evaluation criteria in predicting progression-free survival of lung cancer with certain imaging characteristics
- (2016) Dengxia Yang et al. Thoracic Cancer
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis
- (2015) Sophie Taieb et al. EUROPEAN JOURNAL OF CANCER
- Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma
- (2015) Adeel R. Seyal et al. HEPATOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Severe haemoptysis in patients with nonsmall cell lung carcinoma
- (2014) Keyvan Razazi et al. EUROPEAN RESPIRATORY JOURNAL
- Revised Choi Imaging Criteria Correlate with Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
- (2014) Yeeliang Thian et al. RADIOLOGY
- Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson
- (2014) L. Fournier et al. Diagnostic and Interventional Imaging
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
- (2013) R. Lencioni CLINICAL CANCER RESEARCH
- Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival
- (2013) Navneet Singh et al. MEDICAL ONCOLOGY
- Genetic Changes in Squamous Cell Lung Cancer: A Review
- (2012) Rebecca S. Heist et al. Journal of Thoracic Oncology
- Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
- (2012) Gaia Schiavon et al. PLoS One
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer
- (2008) Simon J. Crabb et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search